Thus, the increasing levels of BChE in advanced AD raise concerns about the efficacy of AChE-selective inhibitors [40,41,42], as BChE acts as a compensatory enzyme when AChE activity declines during disease progression. Here, ACHE is linked to Alzheimer disease.